Entresto, or LCZ696 offers a unique mode of action as it effectively reduces strain and stress on the heart by harnessing the body's natural defense, or protective neurohormonal systems of the heart against heart failure. An enhancement of natriuretic levels and endogenous vasoactive peptides, as well as an inhibition of the renin-angiotensin-aldosterone system makes LCZ696 effectual.
LCZ696 is an efficacious angiotensin receptor-neprilysin inhibitor. As a combination of Sacubitril, a first-in-class neprilysin inhibitor, and the angiotensin receptor antagonist Valsartan) works via augmentation of natriuretic peptides.
LCZ696 is associated with dose-dependent increases in plasma cGMP, angiotensin II and renin activity, which is consistent with this drug’s dual mechanism of action. A typical dosage of 200-400 milligrams of LCZ696 attains 90% of its maximal NEP inhibition metabolically.
The toxicity of LCZ696 has not been determined to be concerning. Common side effects reported by patients in investigational studies include high potassium, dizziness, lower than normal blood pressure, cough and kidney problems.
On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.